SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease
Early Stage Parkinson Disease
About this trial
This is an interventional treatment trial for Early Stage Parkinson Disease focused on measuring Parkinson Disease
Eligibility Criteria
Inclusion Criteria: Diagnosis of idiopathic Parkinson's Disease, Modified Hoehn & Yahr up to stage III, UPDRS motor score (part III) must have a total of at least 10 at baseline. Exclusion Criteria: Diagnosis is unclear or a suspicion of other parkinsonian syndromes, Patients who have undergone surgery for the treatment of PD, Current presence of dyskinesias, Motor fluctuations or loss of postural reflexes, A history of non-response to an adequate course of l-dopa or a dopamine agonist, Patients for whom previously treatment with dopamine agonists needed to terminate because of induction of psychosis (i.e. hallucinations) and /or sleep attacks.
Sites / Locations
- 419
- 413
- 408
- 422
- 403
- 411
- 421
- 410
- 417
- 405
- 420
- 415
- 416
- 406
- 418
- 424
- 412
- 303
- 304
- 301
- 302
- 315
- 313
- 310
- 314
- 312
- 311
- 320
- 321
- 323
- 324
- 325
- 332
- 331
- 329
- 327
- 330
- 328
- 326
- 338
- 339
- 337
- 336
- 340
- 347
- 348
- 346
- 344
- 343
- 345
- 428
- 427
- 429
- 355
- 357
- 356
- 364
- 363
- 362
- 361
- 360
- 373
- 371
- 369
- 374
- 365
- 368
- 366
- 370
- 367
- 376
- 375
- 377
- 378
- 380
- 381
- 379
- 383
- 384
- 382
- 388
- 389
- 387
- 386
- 385
- 391
- 393
- 394
- 396
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Placebo Comparator
1
2
3